HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $52

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

AGIO

0.00

HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ: AGIO) with a Buy and lowers the price target from $54 to $52.